Skip to content

Biodesix, Inc. BDSX Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

NeoGenomics logo
NeoGenomicsNEO
Veracyte logo
VeracyteVCYT
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
Personalis, Inc. logo
Personalis, Inc.PSNL
Guardant Health logo
Guardant HealthGH
GeneDx Holdings logo
GeneDx HoldingsWGS

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s deferred tax assets and other non-current assets?
Biodesix, Inc. (BDSX) reported deferred tax assets and other non-current assets of $7.86M in Q1 2026.
How has Biodesix, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
Biodesix, Inc.'s deferred tax assets and other non-current assets increased by 7.7% year-over-year, from $7.3M to $7.86M.
What is the long-term trend for Biodesix, Inc.'s deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Biodesix, Inc.'s deferred tax assets and other non-current assets has grown at a 18.9% compound annual growth rate (CAGR), from $3.46M to $8.23M.